Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Is it better to pay a premium for explosive growth or hunt for value in a steady giant? This is the central question for investors choosing between Eli Lilly (NYSE:LLY) and Pfizer (NYSE:PFE).

Eli Lilly has transformed into a growth powerhouse led by its blockbuster metabolic treatments for weight loss and diabetes. Meanwhile, Pfizer is repositioning itself through strategic acquisitions to offset patent cliffs and declining pandemic-related revenue. Both companies are giants in the healthcare space, yet they offer vastly different risk and reward profiles for 2026.

The case for Eli Lilly

Eli Lilly develops and markets a wide range of medicines, but its primary focus has shifted heavily toward metabolic health. The company is currently dominated by its GLP-1 platform, which includes blockbuster treatments for diabetes and obesity, making it a standout among pharmaceutical stocks. Its reach is further affected by recent decisions from CVS Health (NYSE:CVS) to limit coverage for specific weight-loss medications on certain insurance plans.

In its latest annual report, filed for FY 2025, revenue reached nearly $65.2 billion, representing a significant 44.7% increase over the previous year. This rapid expansion was accompanied by a net income of approximately $20.6 billion. The company also improved its net margin to 31.7%, up from 23.5% in the prior fiscal year.

As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 1.6x, which measures total debt against shareholder equity. The current ratio is approximately 1.6x, indicating the company's ability to cover short-term obligations with its current assets. Additionally, the company generated nearly $9.0 billion in free cash flow, which is cash from operations minus capital expenditures.

The case for Pfizer

Pfizer operates as a research-based biopharmaceutical company with a global footprint across approximately 200 countries and territories. While its pandemic-era vaccine business has cooled, the company is aggressively expanding its portfolio through significant acquisitions in the oncology space. It relies on a network of managed care entities, including pharmacy benefit managers and health plans, to facilitate patient access to its treatments.

In its latest annual report, filed for FY 2025, the company reported revenue of close to $62.6 billion, which was a slight decrease of roughly 1.6% compared to the prior year. Despite the revenue dip, it achieved a net income of approximately $7.8 billion. Its net margin was approximately 12.4%, showing stability as the company transitions its product mix toward newer therapies.

As of the December 2025 balance sheet, the debt-to-equity ratio is approximately 0.8x, suggesting a lower level of total debt relative to shareholder equity. The current ratio is roughly 1.2x, indicating the company has sufficient liquid assets to cover its upcoming bills. Free cash flow for the year reached nearly $9.1 billion, providing ample capital for dividends and future research.

Risk profile comparison

Lilly faces intense competition from companies developing generic or biosimilar versions of its products once patents expire. The business also deals with heavy revenue concentration, as just six drugs, including Mounjaro and Zepbound, accounted for roughly 82% of its 2025 sales. Furthermore, there is significant uncertainty regarding drug pricing regulations, particularly those stemming from the Inflation Reduction Act and mandatory price negotiations.

Pfizer is currently managing the transition of several key products toward patent expiration, which could lead to significant revenue declines through 2030. It faces stiff competition in the vaccine and oncology space from rivals such as Moderna (NASDAQ:MRNA) and BioNTech (NASDAQ:BNTX). Integrating large acquisitions like Seagen is a complex process, and any failure to commercialize these new assets or resolve ongoing legal settlements could lead to financial impairments.

Valuation comparison

Pfizer appears significantly cheaper than Eli Lilly, which carries a higher Forward P/E and a P/S ratio using sales over the past twelve months.

Valuation metrics include sourcing from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

I'd go with Eli Lilly. Its most recent quarter was one of the most impressive in the company's history. Revenue grew nearly 50% year over year, driven by surging demand for Mounjaro and Zepbound across the diabetes and obesity markets worldwide. Earnings beat estimates by a wide margin and the full-year outlook was raised substantially. Its oral obesity pill, Foundayo, is already on the market and expanding access to patients who prefer not to use injections, though it faces early competition from Novo Nordisk's oral option. Still, that expands an already enormous market even further.

Pfizer is working hard to reinvent itself. Non-COVID products are growing at a healthy pace, the pipeline is active, and a recent acquisition positions it squarely in the obesity drug market that Lilly currently dominates. The pipeline has several key readouts expected over the next 12 months, and management has committed to protecting the dividend.

But Lilly is already the dominant player in the fastest-growing pharmaceutical market of our generation. For a patient investor, that kind of market leadership tends to be worth owning for the long term.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BioNTech Se, Eli Lilly, Moderna, Novo Nordisk, and Pfizer. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy.